California-based Movano Health has submitted a 510(k) premarket notification to the US Food & Drug Administration (FDA) for its first commercial product, the Evie Ring.

The submission has passed the first milestone of the review process, an initial review for completeness, and is now under full review by the FDA.

One of the most critical components of the FDA submission is the ring’s clinical performance. Late in 2022, Movano completed a hypoxia trial with the University of California, San Francisco (UCSF) to assess the accuracy of Evie’s blood oxygen saturation (SpO₂). In comparing the overall accuracy of the ring’s data with data from arterial blood gas data, the Evie Ring achieved an approximate 2% margin of error, well below the FDA guidance of 3.5% for SpO₂.

In a separate nonclinical test completed by Movano per the standard and FDA guidance, pulse was tested over the range of 40 to 240 beats per minute (BPM) and the Evie Ring margin of error was one BPM, also exceeding FDA’s requirements.

“From the outset, our vision for Evie has been to develop a consumer wearable that is beautiful, accessible and personalised, as well as be cleared by the FDA as a medical device,” said John Mastrototaro, CEO of Movano Health. “This first submission to the FDA marks a momentous milestone for our team and sets the stage for future FDA filings. The effort associated with becoming a medical device company is certainly significant, but we believe it’s a highly competitive differentiator and a strong asset when compared to existing wellness solutions. It also is expected to enable significant partnership opportunities with healthcare and other enterprises. We look forward to working with the FDA through the review process.”

The Evie Ring combines health and wellness metrics to give a full picture of one’s health: resting heart rate, heart rate variability, SpO₂, respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. These data are delivered through a mobile app, which aims to simplify how data are presented, moving away from complex graphs and charts, and turning biometric data into actionable insights that will help women make manageable lifestyle changes and take a more proactive approach to mitigating the risks of chronic disease.

Founded in 2018, Movano is developing a suite of purpose-driven healthcare products to bring medical-grade, high-quality data to consumer health devices. Featuring modern form factors, the devices capture a picture of a person’s vital health information and translate the data into personalised and intelligent insights that empower consumers to live healthier and more balanced lives.